Table 1.
Patients’ characteristics
| Variable | Whole pelvic radiotherapy (n = 74) | Extended-field pelvic radiotherapy (n = 52) | p-value |
|---|---|---|---|
| Age (yr) | 54.5 (23–76) | 48 (32–81) | 0.066 |
| Primary tumor diameter (mm) | 41 (10–70) | 46 (10–72) | 0.112 |
| Metastatic pelvic LN sizea) (mm) | 11.7 (6–53) | 13 (6–31.1) | 0.501 |
| <10 | 18 | 11 | 0.909 |
| ≥10 and <20 | 47 | 34 | |
| ≥20 | 9 | 7 | |
| Metastatic pelvic LN number | 2 (1–6) | 2 (1–7) | 0.130 |
| Stage | |||
| IB1 | 16 | 5 | 0.411 |
| IB2 | 8 | 10 | |
| IIA1 | 3 | 1 | |
| IIA2 | 2 | 3 | |
| IIB | 25 | 17 | |
| IIIB | 16 | 14 | |
| IVA | 4 | 2 | |
| Pathologic type | |||
| SCC | 63 | 46 | |
| Adenocarcinoma or ASCC | 11 | 6 | |
| Differentiation | |||
| Well | 1 | 1 | 0.433 |
| Moderately | 70 | 46 | |
| Poorly | 3 | 5 | |
| Pre-treatment SCC antigen level (ng/mL) | 6.48 (0.5–65.29) | 7.4 (0.1–143) | 0.989 |
| Chemotherapy | |||
| Weekly cisplatin | 48 | 31 | 0.364 |
| Cisplatin + 5-FU | 16 | 9 | |
| Cisplatin + paclitaxel | 10 | 12 |
Values are presented as median (range) or number.
LN, lymph node; SCC, squamous cell carcinoma; ASCC, adenosquamous cell carcinoma; 5-FU, 5-fluorouracil.
a)
The size of the metastatic pelvic LN was evaluated via CT and MRI, maximum short-axis dimension of metastatic LN.